Shares of Proteon Therapeutics Inc. hit a wall after the company disclosed that the phase III PATENCY-1 trial of its recombinant human elastase, vonapanitase, missed its primary endpoint of improved primary unassisted patency compared to placebo. Read More
LONDON – The return on investment in pharma R&D continues to slide, with Deloitte LLP's 2016 report projecting returns of 3.7 percent, compared to 10.1 percent in 2010, when the analysis was first conducted. Read More
"We're on the precipice of being able to crack open the science [in neurology]," Amanda Christini, president of Blackfynn Inc., told BioWorld Today. Spun out at the start of 2015 from the University of Pennsylvania, the organization consists of an 11-person team of experts in neurology, neuroscience, computer science, medicine and engineering. Read More
NEW DELHI – Looking to keep up with global trends, Indian pharma has moved to speed up its push toward more digitization, but it has a long way to go before it catches up with advanced countries, pharma industry analysts say. Read More
In order for patients to derive benefit from their medications they have to adhere to the prescribed treatment regimen. In an ideal world dispensed medications for chronic conditions are taken by the patient exactly as prescribed. Sadly, doctors' orders are not always followed for a variety of complex reasons including such factors as the emergence of side effects, length of treatment, the frequency of dosing and severity of the disease to name just a few. As a result medication non-adherence is one of the most serious problems in health care and poses a significant financial drain on the health care system. Read More
Soligenix Inc., of Princeton, N.J., said it priced an underwritten public offering of 1.67 million shares of its common stock and warrants to purchase up to an aggregate of 2.08 million shares of its common stock at a combined offering price of $3.16. Read More
Arbutus Biopharma Corp., of Vancouver, British Columbia, reported results from the multiple-dose cohort of its ongoing phase II study of RNAi candidate ARB-1467 in chronically infected hepatitis B virus (HBV) patients on stable nucleotide/nucleoside therapy, showing a significant reduction of HBsAg. Read More
Cytomx Therapeutics Inc., of South San Francisco, said Bristol-Myers Squibb Co., of New York, has selected a clinical candidate for its CTLA-4 Probody program under the companies' strategic oncology collaboration established in May 2014, resulting in a $2 million milestone payment to Cytomx. Read More
